Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study on the Safety, Tolerability and Efficacy of MTS109 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases, an Investigator-Initiated Trial

NCT07526350 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.

NCT NCT07526350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07526350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study on the Safety, Tolerability and Efficacy of MTS109 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases, an Investigator-Initiated Trial
Lead sponsor
Shanghai Changzheng Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
March 24, 2026
Completion date
April 1, 2029
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca-associated vasculitis (aav), idiopathic inflammatory myopathies, sjogren's syndrome (ss), systemic lupus erythematosus, systemic sclerosis (ssc)